The American Journal of Medicine
Volume 122, Issue 10 , Pages 886-887 , October 2009

The Patient–Physician–Industry–Government Partnership: A Societal Good

References 

  1. Relman AS, Angell M. America's other drug problem. The New Republic. December 16, 2002;27–41
  2. Alpert JS. Doctors and the drug industry: how can we handle potential conflicts of interest?. (editorial) Am J Med. 2005;118:99–100
  3. Blumenthal D. Doctors and drug companies. N Engl J Med. 2004;351:1885–1890
  4. Ross JS, Keyhani S, Korenstein D. Appropriateness of collaborations between industry and the medical profession: physicians' perceptions. Am J Med. 2009;122:955–960

 Funding: None.

 Conflict of Interest: Dr Frishman is Chairman of Medicine at the New York Medical College in Valhalla, New York. He is also a member of the Speakers Bureau for Bristol Myers Squibb and Forest Laboratories, and has served as a paid consultant for Glaxo Laboratories and Boehringer Ingelheim.

PII: S0002-9343(09)00682-2

doi: 10.1016/j.amjmed.2009.07.012

The American Journal of Medicine
Volume 122, Issue 10 , Pages 886-887 , October 2009

Article Tools